糖尿病合并细菌性肝脓肿的诊治进展  

Progress on diagnosis and treatment of pyogenic liver abscess patients with diabetes

作　　者：刘瑶[1] 蒋龙凤[1] 李军[1] 

机构地区：[1]南京医科大学第一附属医院感染科,210029

出　　处：《国际流行病学传染病学杂志》2016年第4期262-266,共5页International Journal of Epidemiology and Infectious Disease

基　　金：江苏省卫生厅医学创新团队与领军人才培养基金（LJ201121）;中国肝炎防治基金会-天晴肝病研究基金（CFHPC20132071）

摘　　要：细菌性肝脓肿为细菌侵入肝脏所引起的感染性疾病，世界范围内的发病率为0．006％～2．2％不等，亚洲地区发病率较高。近年来发现糖尿病是细菌性肝脓肿一个潜在的可控危险因素。糖尿病患者并发肝脓肿的危险性比非糖尿病患者增加3．6倍，且多为隐源性感染。有糖尿病基础的肝脓肿患者与无糖尿病基础的肝脓肿患者相比，临床特征、实验室检查、并发症及治疗方面都有明显差异。此文主要阐述糖尿病合并细菌性肝脓肿的诊治进展。Pyogenic liver abscess （PLA） is a rare infectious disease caused by bacteria with an incidence rate of 0.006%-2.2% worldwide, which is more common in Asia. In recent years, it is found that diabetes is a potential and controllable risk factor of PLA. The risk in diabetic patients complicated with PLA increases 3.6 times higher than in those without diabetes, and cryptogenic infection was the most frequent pathogenesis. There are many differences in clinical features, laboratory tests, complication and treatment between PLA patients with and without diabetes. The advances in diagnosis and treatment of PLA patients with diabetes are reviewed in this article.

关 键 词：肝脓肿 化脓性 糖尿病 诊断 治疗 

分 类 号：R575.4[医药卫生—消化系统]